In this Edition

• Bisphosphonates and denosumab: minimising the risk of osteonecrosis of the jaw (ONJ).
• Risk of severe allergic reactions with ambroxol and bromhexine-containing medicines
  considered small.
• New restriction for hydroxyzine-containing medicines to further minimise the known risk of QT prolongation.
• The Importance of Product Information for Medicines.
• Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter.